OSBPL7-IN-1

Research use only, not for human use.

OSBPL7-IN-1 is an orally active inhibitor of oxysterol binding protein like 7 (OSBPL7). OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression.

OSBPL7-IN-1 is an orally active inhibitor of oxysterol binding protein like 7 (OSBPL7). OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression.(In Vitro):OSBPL7-IN-1 (compound G; 1-10 μM) increase plasma membrane ATP-binding cassette transporter (ABCA1) in cultured human podocytes, and significantly increase ABCA1-dependent cholesterol efflux.(In Vivo):OSBPL7-IN-1 (100 mg/kg; oral gavage; daily; for 28 days) treatment normalizes proteinuria, and prevents renal function decline in mouse models of proteinuric kidney disease.

OSBPL7-IN-1 (compound G or Cpd G; 1-10?μM) increase plasma membrane ATP-binding cassette transporter (ABCA1) in cultured human podocytes, and significantly increase ABCA1-dependent cholesterol efflux.

OSBPL7-IN-1 (100?mg/kg; oral gavage; daily; for 28 days) treatment normalizes proteinuria and prevents renal function decline in mouse models of proteinuric kidney disease. Animal Model:Female Balb/c mice induced by Adriamycin (ADR)Dosage:100?mg/kg.Administration:Oral gavage; daily; for 28 days Result:Normalized proteinuria, and significantly reduced renal fibrosis and renal functional decline.

——

Others

Other Targets

——

——

——

1269826-44-9

463.28

C20H19Cl2F3N2O3

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (269.82 mM)

O[C@H](CCCC1)[C@@H]1NC(c(cn1)cc(-c(cc2)cc(Cl)c2Cl)c1OCC(F)(F)F)=O

——

(-20℃)

With Ice Pack

≥ 2 years